Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.
暂无分享,去创建一个
C D Marsden | B Testa | C. Marsden | P. Carrupt | B. Testa | K. McNaught | A. Carotti | C Altomare | P A Carrupt | A Carotti | C. Altomare | S. Cellamare | P Jenner | K S McNaught | S Cellamare | P. Jenner
[1] S. Ohta,et al. TETRAHYDROISOQUINOLINE AND 1-METHYL-TETRAHYDROISOQUINOLINE ARE PRESENT IN THE HUMAN BRAIN: RELATION TO PARKINSON’S DISEASE , 1987 .
[2] I. Kanazawa,et al. Debrisoquine hydroxylase and Parkinson's disease. , 1993, Advances in neurology.
[3] R. Waring,et al. Xenobiotic metabolism in Parkinson's disease , 1989, Neurology.
[4] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[5] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[6] S. Daniel,et al. Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.
[7] M. Naoi,et al. An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.
[8] C. Marsden,et al. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.
[9] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[10] Y. Mizuno,et al. Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain , 1992, Journal of the Neurological Sciences.
[11] M. Naoi,et al. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.
[12] J. Langston,et al. MPTP and parkinson's disease , 1985, Trends in Neurosciences.
[13] T. Niwa,et al. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.
[14] C. Marsden,et al. Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Neuroreport.
[15] S. Ohta,et al. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. , 1986, Biochemical and biophysical research communications.
[16] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[17] S. Ohta,et al. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydro-isoquinoline in foods: compounds related to Parkinson's disease. , 1988, Life sciences.
[18] P. Carrupt,et al. Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and 3D-quantitative structure-activity relationships. , 1995, Biochemical pharmacology.
[19] C. Marsden,et al. Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.
[20] H. Rommelspacher,et al. Tetrahydroisoquinolines and beta-carbolines: putative natural substances in plants and mammals. , 1985, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[21] S. Ohta,et al. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate , 1996, Neuroscience Letters.
[22] R. Ramsay,et al. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. , 1994, The Journal of biological chemistry.
[23] T. Origitano,et al. Rat brain salsolinol and blood-brain barrier , 1981, Brain Research.
[24] C. Olanow,et al. Neurodegeneration and Neuroprotection in Parkinson's Disease , 1996 .
[25] T. Nagatsu. Isoquinoline neurotoxins in the brain and Parkinson's disease , 1997, Neuroscience Research.
[26] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[27] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Naoi,et al. Oxidation of N‐Methyl‐1,2,3,4‐Tetrahydroisoquinoline into the N‐Methyl‐Isoquinolinium Ion by Monoamine Oxidase , 1989, Journal of neurochemistry.
[29] R. Ramsay,et al. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. , 1986, Biochemical and biophysical research communications.
[30] Y. Mizuno,et al. Effect of Dopamine, Dimethoxyphenylethylamine, Papaverine, and Related Compounds on Mitochondrial Respiration and Complex I Activity , 1996, Journal of neurochemistry.
[31] Zhenxin Zhang,et al. Worldwide occurrence of Parkinson's disease , 1993 .
[32] M. Naoi,et al. A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. , 1989, Biochemical and biophysical research communications.
[33] N. Hattori,et al. An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease , 1994 .
[34] C. Marsden,et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.
[35] T. Nagatsu,et al. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. , 1993, Advances in neurology.
[36] G. Sobue,et al. A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain , 1997, Neuroscience Letters.
[37] T. Niwa,et al. Presence of tetrahydroisoquinoline, a parkinsonism-related compound, in foods. , 1989, Journal of chromatography.
[38] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[39] J. Langston,et al. Neurotoxins, parkinsonism and Parkinson's disease. , 1987, Pharmacology & therapeutics.
[40] K. Kikuchi,et al. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[41] L. Forno. Pathology of Parkinson's disease , 1981 .
[42] Y. Mizuno,et al. Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain , 1988, Journal of the Neurological Sciences.
[43] O. Phillipson,et al. 1, 2, 3, 4‐Tetrahydro‐2‐Methyl‐4, 6, 7‐Isoquinolinetriol Depletes Catecholamines in Rat Brain , 1993, Journal of neurochemistry.
[44] S. Ohta,et al. Novel Endogenous 1,2,3,4‐Tetrahydroisoquinoline Derivatives: Uptake by Dopamine Transporter and Activity to Induce Parkinsonism , 1998, Journal of neurochemistry.
[45] R. Ramsay,et al. Studies on the Characterization of the Inhibitory Mechanism of 4′‐Alkylated 1‐Methyl‐4‐Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport Particles , 1994, Journal of neurochemistry.
[46] M. Naoi,et al. N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. , 1995, Free radical biology & medicine.
[47] A. Szczudlik,et al. Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology , 1997, Biological Psychiatry.
[48] R. Ross. Drug-Induced Parkinsonism and Other Movement Disorders , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[49] T. Niwa,et al. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. , 1988, Journal of chromatography.
[50] C. Marsden,et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[51] J. Cashaw. Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography. , 1993, Journal of chromatography.
[52] G. Cohen,et al. Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake. , 1971, The Journal of pharmacology and experimental therapeutics.
[53] T. Niwa,et al. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains. , 1987, Biochemical and biophysical research communications.
[54] J. Barker,et al. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum , 1989, Brain Research.
[55] C. Marsden,et al. New insights into the cause of Parkinson's disease , 1992, Neurology.
[56] J. Cooper,et al. Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.
[57] D. D. Di Monte,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.
[58] S. Ohta,et al. Cytochrome P450 isozymes catalyzing 4‐hydroxylation of parkinsonism‐related compound 1,2,3,4‐tetrahydroisoquinoline in rat liver microsomes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[59] H. Rommelspacher,et al. β-Carbolines and Tetrahydroisoquinolines: Detection and Function in Mammals , 1991, Planta medica.
[60] C. Hoppel,et al. Dopaminergic Neurotoxicity In Vivo and Inhibition of Mitochondrial Respiration In Vitro by Possible Endogenous Pyridinium‐Like Substances , 1991, Journal of neurochemistry.
[61] S. Ohta,et al. 1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.
[62] H. Nakamura,et al. Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XVI. Characteristics of the membrane-bound dehydrogenase in Candida utilis and Saccharomyces cerevisiae. , 1970, Archives of biochemistry and biophysics.
[63] J. Smyth,et al. Progress in Clinical and Biological Research , 1979 .
[64] G. Román,et al. Worldwide occurrence of Parkinson's disease: an updated review. , 1993, Neuroepidemiology.
[65] C. Marsden,et al. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1996, Biochemical pharmacology.
[66] M. Naoi,et al. Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. , 1990, Journal of chromatography.
[67] C. Marsden,et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease , 1997, The Lancet.
[68] K. Jones,et al. Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice , 1988, Neuroscience Letters.
[69] Y. Mizuno,et al. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.
[70] D. Greenblatt,et al. Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. , 1987, Biochemical and biophysical research communications.
[71] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[72] M. Naoi,et al. N‐Methylation of Dopamine‐Derived 6,7‐Dihydroxy‐1,2,3,4‐Tetrahydroisoquinoline, (R)‐Salsolinol, in Rat Brains: In Vivo Microdialysis Study , 1992, Journal of neurochemistry.
[73] A. Zuddas,et al. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra , 1989, Brain Research.
[74] D. Acosta,et al. Changes in glutathione and cellular energy as potential mechanisms of papaverine-induced hepatotoxicity in vitro. , 1991, Toxicology and applied pharmacology.
[75] R. Ramsay,et al. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.
[76] A H Schapira,et al. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. , 1997, Brain research.
[77] C. Olanow,et al. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders , 1996 .
[78] M. Naoi,et al. Dopamine‐Derived 1‐Methyl‐6,7‐Dihydroxyisoquinolines as Hydroxyl Radical Promoters and Scavengers in the Rat Brain: In Vivo and In Vitro Studies , 1995, Journal of neurochemistry.
[79] Y. Mizuno,et al. Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture , 1997, Brain Research.
[80] S. Markey,et al. Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease , 1992, Brain Research.
[81] R. Deitrich,et al. Biogenic amine-aldehyde condensation products: tetrahydroisoquinolines and tryptolines (beta-carbolines). , 1980, Annual review of pharmacology and toxicology.
[82] A. Harvey. Natural and synthetic neurotoxins , 1993 .
[83] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[84] K. Suzuki,et al. Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. , 1989, Biochemical and biophysical research communications.